0
Research Notes
Nonadherence to angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers among high-risk patients with diabetes in Medicare Part D programs
Yi Yang, MD, PhD; Vennela Thumula, BPharm; Patrick F. Pace, PhD; Benjamin F. Banahan, PhD; Noel E. Wilkin, BPharm, PhD; William B. Lobb, BPharm, PhD
J Am Pharm Assoc (2003) 2010;50:527-531. doi:10.1331/JAPhA.2010.09071

Abstract

Objectives  To identify predictors of nonadherence to angiotensin-converting enzyme inhibitors (ACEIs) and/or angiotensin II receptor blockers (ARBs) and to assess the association between nonadherence to ACEIs/ARBs and potentially avoidable hospitalizations (PAHs) among elderly high-risk patients with diabetes.

Methods  Medicare Part D enrollees from six states who had diabetes and coexisting hypertension and/or renal disease, were aged 65 years or older, and who had filled at least one prescription for ACEIs/ARBs in the first 6 months of 2006 were included in this retrospective cohort study. The primary outcomes of interests were patient nonadherence to ACEI/ARB therapy, which was defined as a proportion of days covered (PDC) less than 0.8 and PAH for diabetes during the patient follow-up period (July 1, 2006, to March 31, 2007).

Results  A total of 599,141 patients (mean [±SD] age 75.6 ± 7.3 years, 66% women, 63% white, 15% black, and 9% Hispanic) were included. Among them, 46% were nonadherent to ACEI/ARB therapy and 6.3% had a PAH during the follow-up period. In multivariate logistic regressions, patients with diabetes and both hypertension and renal disease and patients with diabetes and renal disease only were 24% and 15% more likely, respectively, to be nonadherent to ACEI/ARB therapy compared with patients with diabetes and hypertension. Black and Hispanic patients were also more likely to be nonadherent to ACEI/ARB therapy. Nonadherence to ACEI/ARB therapy was associated with a 5% increase in the likelihood of PAH.

Conclusion  Adherence to ACEI/ARB therapy is suboptimal among elderly high-risk patients with diabetes enrolled in Medicare Part D programs from six states, and nonadherence to ACEIs/ARBs is associated with a slightly increased risk for PAH.

Sign In
APhA Members 
Welcome to JAPhA.org! Please log in below using your APhA username and password. Update your APhA profile.
Not a Subscriber
New to JAPhA? Become an APhA member to receive a full subscription to both the print and online editions.

OR

Register for a FREE limited account to benefit from personalization features such as alerts.

References

Arauz-Pacheco C, Parrott MA, Raskin P. Hypertension management in adults with diabetes.  Diabetes Care. 2004;27(suppl 1):S65–7.[PubMed]
 
Molitch ME, DeFronzo RA, Franz MJ, et al. Nephropathy in diabetes.  Diabetes Care. 2004;27(suppl 1):S79–83.[PubMed]
 
 Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy.  Lancet. 2000;355:253–9.[PubMed][CrossRef]
 
Brenner BM, Cooper ME, Zeeuw  de D, Keane WF et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.  N Engl J Med. 2001;345(12):861–9.[PubMed]
 
Estacio RO, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension.  N Engl J Med. 1998;338:645–52.[PubMed]
 
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.  N Engl J Med. 1993;329:1456–62.[PubMed]
 
Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes.  N Engl J Med. 2008;359:1565–76.[PubMed]
 
 American Diabetes Association. Standards of medical care in diabetes–2009.  Diabetes Care. 2009;32(suppl 1):S13–61.[PubMed]
 
Rodbard HW, Blonde L, Braithwaite SS, et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus.  Endocr Pract. 2007;13(suppl 1):1–68.[PubMed]
 
Hertz RP, Unger AN, Lustik MB.  Adherence with pharmacotherapy for type 2 diabetes: a retrospective cohort study of adults with employer-sponsored health insurance.  Clin Ther. 2005;27:1064–73.[PubMed]
 
Ho PM, Rumsfeld JS, Masoudi FA, et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus.  Arch Intern Med. 2006;166:1836–41.[PubMed]
 
Lau DT, Nau DP.  Oral antihyperglycemic medication nonadherence and subsequent hospitalization among individuals with type 2 diabetes.  Diabetes Care. 2004;27:2149–53.[PubMed]
 
 Agency for Healthcare Research and Quality. Guide to prevention quality indicators: revision 3.1. Accessed at www.qualityindicators.ahrq.gov/downloads/pqi/pqi_guide_v31.pdf, December 18,  2009.
 
 Cerner Multum. Multum Lexicon. Accessed at www.multum.com/Lexicon.htm, December 18,  2009.
 
Peterson AM, Nau DP, Cramer JA, et al. A checklist for medication compliance and persistence studies using retrospective databases.  Value Health. 2007;10(1):3–12.[PubMed]
 
Rubin RR.  Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus.  Am J Med. 2005;118(suppl 5A):27–34S.
 
Trinacty CM, Adams AS, Soumerai SB, et al. Racial differences in long-term adherence to oral antidiabetic drug therapy: a longitudinal cohort study.  BMC Health Serv Res. 2009;9:24.[PubMed]
 
Shaya FT, Du D, Gbarayor CM, et al. Predictors of compliance with antihypertensive therapy in a high-risk medicaid population.  J Natl Med Assoc. 2009;101(1):34–9.[PubMed]
 
Haynes RB, Ackloo E, Sahota N, et al. Interventions for enhancing medication adherence.  Cochrane Database Syst Rev. 2008;CD000011.
 
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Please read the other comments before you post yours. Comments are moderated and will appear on the site at the discertion of the editorial staff.
* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe



Related Content

Customize your page view by dragging & repositioning the boxes below.

JAPhA Articles
Topic Collections
PubMed Articles
Advertisement
 
  • Print
  • PDF Download
  • Email
  • Share
  • Get Citation
  • Submit Comment
  • Article Alerts
    Please Wait... Processing your request... Please Wait.
    You must sign in to sign-up for alerts.

    Please confirm that your email address is correct, so you can successfully receive this alert.

  • Letters To Editor
  • Reprints